Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples